Adjuvant therapy with imatinib for an incompletely resected multilobular tumour of bone in a dog

Lee Sh, Kim Dh, K Bae, Jeong Sw, Yoon Ka, Yoon Hy, Do Sh, B Kim and Kim Jh
Additional contact information
Lee Sh: Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Kim Dh: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
K Bae: Department of Veterinary Biochemistry, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Jeong Sw: Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Yoon Ka: Department of Veterinary Biochemistry, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Yoon Hy: Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
Do Sh: Department of Veterinary Clinical Pathology, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea
B Kim: Department of Physiology, School of Medicine, Konkuk University, Seoul, Republic of Korea
Kim Jh: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea

Veterinární medicína, 2022, vol. 67, issue 11, 590-597

Abstract: A 5-year-old neutered male Shiba Inu dog presented with a history of oral bleeding, dysphagia, and depression for 3 weeks. The physical examination revealed a firm mass in the right caudal palatal region along the level of PM4-M2. On the computed tomography, the mass was round-to-oval in shape and 22 mm × 30 mm × 15 mm in size. The mass contained multiple bone attenuated materials with a palatal bone lysis of 4 mm × 6 mm. A complete resection of the mass was proposed; however, the owner declined due to the risk of complications associated with the radical surgery. Therefore, a palliative resection and biopsy of the mass were performed. On the histological examination, the mass was diagnosed as grade 2 multilobular tumour of bone (MTB). Since the mass was incompletely resected, adjuvant therapy was pursued along with targeted therapy using a tyrosine kinase inhibitor. The tumour cells showed overexpression of the receptor of tyrosine kinase for c-KIT, PDGFR-α, PDGFR-β, and FGFR1 compared to normal tissue cells. Additionally, the cytotoxic effect of imatinib on the MTB cells was confirmed in vitro. Four weeks postoperatively, the administration of imatinib and carprofen was initiated and continued for 259 days. The patient maintained a good functional outcome for 306 days after the initial presentation.

Keywords: canine; carprofen; sarcoma; target therapy; tyrosine kinase inhibitor (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://vetmed.agriculturejournals.cz/doi/10.17221/85/2021-VETMED.html (text/html)
http://vetmed.agriculturejournals.cz/doi/10.17221/85/2021-VETMED.pdf (application/pdf)
free of charge

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:caa:jnlvet:v:67:y:2022:i:11:id:85-2021-vetmed

DOI: 10.17221/85/2021-VETMED

Access Statistics for this article

Veterinární medicína is currently edited by Ing. Helena Smolová Ph.D.

More articles in Veterinární medicína from Czech Academy of Agricultural Sciences
Bibliographic data for series maintained by Ivo Andrle ().